A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma (CAPAFOUR)

  • End date
    Aug 10, 2023
  • participants needed
  • sponsor
    Cantargia AB
Updated on 24 May 2022


This study will consider the safety and effectiveness of a study drug, CAN04, in combination with FOLFIRINOX, in the treatment of metastatic pancreatic ductal adenocarcinoma.

Condition Metastatic Pancreatic Ductal Adenocarcinoma
Clinical Study IdentifierNCT04990037
SponsorCantargia AB
Last Modified on24 May 2022


Yes No Not Sure

Inclusion Criteria

The subject is capable to understand and willing to provide written informed consent before any study-related activities (study-related activities are any procedures that would not have been performed during normal management of the subject's disease)
The subject is at least 18 years of age
The subject has been diagnosed with stage IV PDAC (Pancreatic Ductal Adenocarcinoma) and is amenable to first-line systemic therapy. The subject must have measurable disease that is histologically or cytologically confirmed
The subject has an ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1
The subject has a primary or metastatic lesion amenable to biopsy and is willing to undergo repeat biopsies, unless a biopsy would not be safe in the opinion of the investigator and in agreement by the sponsor and medical monitor (or designee)
The subject has clinically adequate bone marrow, hepatic, and renal function based on clinical laboratory test values at screening within the following ranges
Creatinine clearance >30 mL/min calculated by Cockcroft-Gault formula
Haemoglobin >90 g/L (blood transfusions during the screening period are not allowed)
Absolute neutrophil count >1.5 × 109/L (usage of growth factors, such as G-CSF (Granulocyte Colony-Stimulating Factor), during the screening period is not allowed)
Platelets >100 × 109/L
Total bilirubin <1.5 × ULN unless due to Gilbert's syndrome
AST and ALT ≤3 × ULN (or <5 × ULN for subjects with hepatic metastases)
The subject has a QT interval corrected using Fridericia's formula (QTcF) of ≤ 480
milliseconds at screening
Female subjects of childbearing potential (more info can be found in the protocol) and male subjects with female partners of childbearing potential must be willing to adhere to contraceptive requirements as detailed in the protocol, from at least 1 month prior to study entry to at least 4 months after the last dose of study treatment
The subject has suitable venous access for safe drug administration and the studyrequired drug concentration and pharmacodynamic sampling

Exclusion Criteria

Subjects who have received previous radical radiotherapy, chemotherapy, or investigational therapy for the treatment of metastatic disease
Prior treatment with 5-FU or gemcitabine administered as a radiation sensitiser during and up to 4 weeks after radiation therapy, is allowed; however, if there is lingering toxicity (Grade >1), then the sponsor should be consulted
If a subject received adjuvant or neoadjuvant chemotherapy, tumour recurrence or disease progression must have occurred no sooner than 6 months after completing the last dose
Subjects with uncontrolled brain metastases; however, subjects are allowed if they
Subjects with endocrine or acinar pancreatic carcinoma
Subjects with an active severe infection requiring parenteral antibiotics at the time of enrolment or subjects currently receiving oral antibiotics as a continuation of a previous course of parenteral antibiotics
have been previously treated with surgery, whole-brain radiation, and/or
stereotactic radiosurgery and are considered controlled (with ≤10 mg/day of
Subjects with a serious uncontrolled medical disorder that, in the opinion of the investigator or medical monitor, makes it unwise for the subject to participate in the study or that might jeopardise compliance with the protocol
prednisone or equivalent) at the time of receiving the first dose of CAN04
Subjects with psychiatric illness/social circumstances that would limit compliance with study requirements and substantially increase the risk of AEs (Adverse Events) or has compromised ability to provide written informed consent
For asymptomatic subjects, screening brain imaging is not required
Subjects with an active second invasive malignancy with the exception of stable prostate cancer on watchful waiting
Subjects with uncontrolled or significant cardiovascular disease defined as NYHA (New York Heart Association) classification III or IV
Subjects with peripheral sensory neuropathy Grade ≥2
Subjects with congenital long QT syndrome
Subjects with a history of autoimmune disease requiring systemic immunosuppressive therapy (daily prednisone equivalent doses >10 mg/day)
Subjects with known hepatitis B virus surface antigen seropositive or detectable hepatitis C infection viral load. NOTE: Subjects who have positive hepatitis B core antibody or hepatitis B surface antigen antibody can be included but must have an undetectable hepatitis B viral load
Subjects with a known history of any other relevant congenital or acquired immunodeficiency other than HIV infection. NOTE: Subjects testing positive for HIV are NOT excluded from this study, but HIV- positive subjects must meet the following
Have not had an opportunistic infection within the past 12 months. Subjects on prophylactic antimicrobials can be included in the study
Should be on established antiretroviral therapy for at least 4 weeks
Have an HIV viral load less than 400 copies/mL prior to enrolment
Subjects who have had a hospitalization for bowel obstruction within 12 weeks prior to enrolment
Have CD4+ T-cell (CD4+) counts ≥350 cells/µL
Subjects with a known bleeding disorder or coagulopathy. NOTE: Subjects on stable anticoagulant therapy are allowed at the discretion of the investigator; however, these subjects should be monitored more frequently
Subjects with a known or suspected allergy to any study treatment or related products, including platinum-based chemotherapeutic agents
Female subjects who are pregnant or breastfeeding or trying to become pregnant
Subjects who receive a live vaccination, etanercept, or other TNF-α (Tumor Necrosis
Factor-alpha) inhibitors during or just prior to (within 28 days of first dose
of study treatment) participation in this study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note